Related Experiment Videos
[Clinical studies on glycoprotein IIb/IIIa receptor antagonist]
L H Rasmussen1, S E Husted, P M Clemmensen
1Hjertecentret, kardiologisk afdeling S, Aalborg Sygehus Syd.
Ugeskrift for Laeger
|November 30, 2000
Summary
Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents crucial for treating acute coronary syndromes (ACS). This review covers their pharmacology, clinical trial results, and use in ACS and percutaneous coronary interventions.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Context:
- Platelet activation is central to acute coronary syndromes (ACS) pathophysiology.
- Inhibiting platelet function is a cornerstone of ACS pharmacological treatment.
- Glycoprotein IIb/IIIa inhibitors represent a potent class of antiplatelet agents.
Purpose:
- To explore platelet inhibition strategies.
- To review the pharmacology of glycoprotein IIb/IIIa inhibitors.
- To examine clinical trial outcomes and current applications of these inhibitors in ACS and percutaneous coronary interventions.
Summary:
- Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents used in managing ACS.
- This review details their mechanism of action, clinical efficacy, and therapeutic role.
- Current applications in ACS treatment and post-percutaneous coronary intervention settings are discussed.
Impact:
- Provides a comprehensive overview of glycoprotein IIb/IIIa inhibitors for clinicians and researchers.
- Highlights the importance of potent platelet inhibition in cardiovascular medicine.
- Informs therapeutic decisions in managing acute coronary syndromes and related interventions.